The Epidemic of Depression: When Science Doesn’t Correct Itself


Depression is a silent epidemic and both Millennial and Gen. Z generations are depressed. Those statements can be found in media but the idea underlying them is that we are facing an epidemic of depression. The perception of the epidemic of depression has generated social and academic drawback from psychiatry. Nevertheless, I will argue that depression is not an epidemic; rather, the next hypothesis can explain the current situation: the practical implications of the epistemic problems of psychiatry, which are grounded in the process of medicalizing depression, haven’t been reviewed. Epidemiological papers about the epidemic of depression and the perceived rise of depression cases hinder affirming that depression is an epidemic. Those papers search for alternative explanatory hypothesis that are related with psychiatric epistemic problems. That relationship originated through the non-epistemic values present in the process of medicalizing depression. The epistemic problems caused by such values haven’t been corrected yet. This overview allows me to propose that the process of medicalizing depression shares characteristics with the processes of pharmaceuticalisation and disease mongering. Those processes of medicalization are characterized by being rooted in lack of epistemic trust.
  • Referencias
  • Cómo citar
  • Del mismo autor
  • Métricas
Abraham, J. (2008). Sociology of pharmaceuticals development and regulation: a realist empirical research programme. Sociology of Health & Illness, 30(6), 869-885.

Abraham, J. (2010). Pharmaceuticalization of society in context: Theoretical, empirical and health dimensions. Sociology, 44(4), 603-622.

Acelay, C. (2018). Depresión, la pandemia femenina. El mundo. 1 de abril.

Albalat Peraita, B. (2022). Milenial y generación Z: ¿Por qué son la generación deprimida? The Conversation. 1 de abril.

Albarracin, D., Ducousso-Lacaze, A., Cohen, D., Gonon, F., Keller, P. y Minard, M. (2015). There is no cure for existence: on the medicalization of psychological distress. Ethical Human Psychology and Psychiatry, 17, 149-158.

Andersen, L. M. (2017). Mechanism and reduction in psychiatry. En M. Massimi, J-W. Romejn y G. Schurz (Eds.), EPSA15 Selected Papers: The 5th conference of the European Philosophy of Science Association in Düsseldorf (pp. 111-124). Amsterdam: Springer.

Andrews, P. W., Thomson, J. A., Amstadter, A., Neale, M. C., (2012). Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. Frontiers Psychology, 24(3).

Avery, R. J., Eisenberg, M. D., Simon, K. I. (2012). The impact of direct-to-consumer televisión and magazine advertising on antidepressant use. Journal of Health Economics, 31(5), 705-718.

Ballesteros, S. (2017). La depresión, epidemia del siglo XIX. Ser. 7 de abril.

Baxter, A., Scott, K., Ferrari, A., Norman, R., Vos, T., Whiteford, H. (2014). Challenging the myth of an “epidemic” of common mental disorders: Trends in the global prevalence of anxiety and depression between 1990 and 2010. Depression and Anxiety, 31(6), 1-11.

Casarotto PC, G. M. (2021). Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell, 184(5), 1299-1313.

Caspi, A., Houts, R., Ambler, A., Danese, A., Elliott, M. L., Hariri, A., Harrington, H., Hogan, S., Poulton, R., Ramrakha, S., Rasmussen, L. J. H., Reuben, A., Richmond-Rakerd, L., Sugden, K., Wertz, J., Williams, B. S. y Moffitt, T. E. (2020). Longitudinal Assessment of Mental Health Disorders and Comorbidities Across 4 Decades Among Participants in the Dunedin Birth Cohort Study. JAMA Network Open, 3(4), 203-221.

Castells, M. (2009). Comunicación y poder. Madrid: Alianza.

Charland, L. C. (2013). Why psychiatry should fear medicalization. En K. W. Fulford, M. Davies, R. G. Gipps, G. Graham, J. Z. Sadler, G. Stanghellini, et al., (Eds.), The oxford handbook of philosophy and psychiatry: International perspectives in philosophy and psychiatry (pp. 159-175). Oxford: Oxford University Press.

Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Orawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P., Geddes, J. R. (2018). Comparative efficacy of acceptability of 21 antidepressants drugs for the acute treatment of adults with major depressive disorder: a systematic review and netwotk meta-analysis. Lancet, 391(10128), 1357-1366.

Clarke, A. E., Mamo, L., Fosket, J. R., Fishman, J. R., Shim, J. K. (2010). Biomedicalization: Technoscience, health, and illness in the U.S. Duke University Press.

Cohen, D. y Jacobs, D. H. (2007). Randomized controlled trials of antidepressants: clinically and scientifically irrelevant. Debates in Neuroscience, 1, 44-54.

Compton, W. M., Conway, K. P., Stinson, F. S., Grant, B. F. (2006). Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. American Journal of Psychiatry, 163(12), 2141-2147.

Conrad, P. (2007). The medicalization of society: On the transformation of human condition into treatable disorders. Baltimore: The John Hopkins University Press.

Cosci, F., Chouinard, G. (2019). The monoamine hypothesis of depression revisited: could it mechanistically novel antidepressant strategies? En J. Quevedo, A. Carvalho y C. A. Zarate (Eds.), Neurobiology of Depression: Road to novel Therapeutics. Amsterdam: Elsevier.

Cristea, I. A., Cuijpers, P. (2015). What if placebo effect explained all the activity of depression treatments? World Psychiatry, 14(3), 310-311.

Davies, J., Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressants withdrawal effects: are guidelines evidence-base? Addictive Behaviors, 97, 111-121.

De Celis Sierra, M. (2018). El ultimo metaanálisis sobre antidepresivos: nada nuevos bajo el sol. Clínica contemporánea, 1(9), 1-5.

De Vries, Y. A., Roest, A. M., de Jonge, P., Cuijpers, P., R., M. M., Bastaasen, J. A. (2017). The cumulative effect of reporting and citation biases on the apparent efficacy of treatments: The case of depression. Psychological Medicine, 48(15), 2453-2455.

Foucault, M. (1971). Madness and Civilisation. Londres: Travistock.

Frances, A. (2014). ¿Somos todos enfermos mentales?: Manifiesto contra los abusos de la psiquiatría. Barcelona: Editorial Ariel.

Gahemi, N. (2010). The rise and fall of the biopsychosocial model: Reconciling art and science in psychiatry. Baltimore: John Hopkins University Press.

González-Moreno, M., Saborido, C., Teira, D. (2015). Disease-mongering through clinical trials. Studies in History and Philosophy of Biological and Biomedical Sciences, 51, 11-18.

Grajales, M. (2021). Depresión y ansiedad: La epidemia silenciosa que aceleró el Covid-19. Forbes. 23 de diciembre.

Greenslit, N. P., Kaptchuk, T. J. (2012). Antidepressants and advertising: psychopharmaceuticals in crisis. Yale Journal of Biomedicine, 85(1), 153-158.

Grow, J. M., Park, J. S. y Ham, X. (2006). “Your life is waiting!” Symbolic meanings in direct-to-consumer antidepressants advertising. Journal of Communication Inquiry, 30(2), 163-188.

Harrington, A. (2019). Mind fixed: psychiatry’s troubled research for the biology of mental illness. Nueva York: W. W. Northon & Company.

Healy, D. (2004a). The Creation of Psychopharmacology. Cambridge: Harvard University Press.

Healy, D. (2004b). Shaping the intimate: Influences on the experience of everyday nerves. Social Studies of Science, 34(2), 219-245.

Hidaka, B. (2012). Depression as a disease of modernity: Explanations for increasing prevalence. Journal of Affective Disorders, 140(3), 205-214.

Horwitz, A., Wakefield, J. (2007). The loss of sadness: How psychiatry transformed normal sorrow into depressive disorder. Nueva York: Oxford University Press.

Horwitz, A. (2010). How and age of anxiety became an age of depression. The Milkank Quarterly, 88(1), 112-138.

Illich, I. (1975). Nemesis médica: la expropiación de la salud. Barral Editores.

Infosalus (2022). La OMS alerta de que la prevalencia mundial de ansiedad y depresión aumentó en un 25 % en el primer año de la pandemia. Infosalus. 2 de marzo.

Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., Wang, P. (2010). Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. American Journal of Psychiatry, 167(7), 748-751.

Ioannidis, J. (2008). Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philosophy, Ethics, and Humanities in Medicine, 3(14).

Ioannidis, J. (2012). Why science is not necessarily self-correcting. Perspectives on Psychological Science, 7(6), 645-654.

Jeong, A. (2021). Gen Z most stressed by coronavirys, citing pandemic toll on careers, education and relationships, poll says. The Washington Post. 7 de diciembre.

Kaczmarek, E. (2019). How to distinguish medicalization from over-medicalization? Medicine, Health Care and Philosophy, 22, 119-228.

Kendler, K. (2008). Explanatory models for psychiatric illness. American Journal of Psychiatry, 165(6), 695-702.

Kessler, R., Chiu, W. T., Delmer, O., Merikangas, K., Walters, E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617-627.

Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., Jhonson, B. T. (2008). Initial severity and antidepressant Benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45.

Kirsch, I. (2010). The emperor’s new drugs: Exploding the antidepressant myth. Nueva York: Basic Books.

Kirsch, I. (2014). Antidepressants and the placebo effect. Zeitschrift fur Psychologie, 222(3), 128-134.

Kluth, A. (2020). An epidemic of depression and anxiety among young adults. Bloomber. 22 de agosto.
Koves, V., Brugha, T., Carta, M. G., Lehtinen, V., Agermeyer, M. C., Bernal, M., Xavier, M., Kittel, F., Fryers, T., Aongusa, B. N., Poulsen, H. D., Pull, C., Abad, J. M. H., Katschnig, H., Madianos, M. G., Dalgard, O. S., Bijl, R., Rutz, W., Henderson, J. H., McColl, K. (2004). The state of mental health in the European Union. European Comission.

La Sexta (2021). Cientos de personas se manifiestan en Madrid para clamar al Gobierno un plan de prevención del suicidio. La Sexta. 11 de septiembre.

Liu, B. L. (2017). From serotonin to neuroplasticity: evolvement of theories from major depressive disorder. Frontiers in Cellular Neuroscience, 11(305).

Liu, Q., He, H., Yang, J., Feng, X., Zhao, F., Lyu, J. (2020). Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. Journal of Psychiatric Research, 126, 134-140.

McHenry, L. (2005). Ethical issues in psychopharmacology. Law, Ethics and Medicine, 32, 405-410.

Millhouse, T., Porter, J. (2015). A brief history of the development of antidepressant drugs: from monoamines to glutamate. Experimental and Clinical Psychopharmacology, 23(1), 1-21.

Moncrieff, J., Kirsch, I. (2005). Efficacy of antidepressants in adults. British Medical Journal, 331(7509), 155-157.

Moncrieff, J. (2008). The creation of the concept of an antidepressant: An historical analysis. Social Science & Medicine, 66(11), 2346-2355.

Mouzo, J. (2021). La epidemia que subyace tras la covid: los casos de depresión y ansiedad crecen más de un 25 % en el mundo. El País. 9 de octubre.

Moyniham, R. (2012). Disease-mongering. The Politics of Medicine (e-Encyclopedia).

Moynihan, R., Heath, I., Henry, D. (2002). Selling sickness: The pharmaceutical industry and disease monguering. British Medical Journal, 324, 886-891.

Mulder, R. (2008). An epidemic of depression or the medicalization of distress?. Perspectives in Biological Medicine, 51(2), 238-250.

Parens, E. (2011). On good and bad forms of medicalization. Bioethics, 27, 28-35.

Parker, G. (2007). Is depression overdiagnosed? Yes. British Journal of Medicine, 335(7615), 328-329.

Parnas, J. (2014). The RDoC program: psychiatry without psyche? World Psychiatry, 13(1), 46-47.

Procopio, M. (2008). The multiple outcomes bias in antidepressants research. Medical Hypotheses, 65(2), 395-399.

Read, J., Williams, J. (2018). Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality, and withdrawal effects. Current Drug Safety, 13(3), 176-186.

Rose, N. (2006). Disorders without borders? The expanding scope of psychiatric practice. BioSocieties, 1(4), 465-484.

Ross, M. (2015). The truth behind U of T’s anti-psychiatry scholarship. Hiffpost. 17 de octubre.

Roura, N. (2022). El cerebro millennial: Una aproximación neurocientífica a lo que nos pasa. Buenos Aires: Random Comics.

Schraer, R. (2020). Depression doubles during coronavirus pandemic. BBC News. 18 de agosto.

Sholl, J. (2017). The muddle of medicalization: patologizing or medicalizing? Theory of Medicine and Bioethics, 38, 265-278.

Shorter, E. (1998). A History of Psychiatry: From the Era of the Asylum to the Age of Prozac. Hoboken: John Wiley & Sons.

Shorter, E. (2008). Before prozac: The troubled history of mood disorders in psychiatry. Nueva York: Oxford University Press.

Stegenga, J. (2018). Medical Nihilism. Oxford: Oxford University Press.

Strawbridge, R., Young, A., Cleare, A. J. (2017). Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatric Disease and Treatment, 13, 1245-1262.

Stucchi-Portocarrero, S. (2017). ¿Realmente existe una “epidemia de depresión”? Revista de Neuropsiquiatría, 80(4), 261-264.

Tolosa, L. (2021). “¡Vete al médico!”: el grito de un diputado del PP a Errejón en el congreso mientras hablaba de los problemas de salud mental. El País. 17 de marzo.

Twenge, J. (2019). The mental health crisis among America’s youth is real – and staggering. The Conversation, 14 de marzo.

Vidal, F., Ortega, F. (2021). ¿Somos nuestro cerebro?: La construcción del sujeto cerebral. Madrid: Alianza.

Vigo, D., Thronicroft, G., Atun, R. (2016). Estimating the true global burden of mental illness. Lancet Psyachiatry, 3(2), 171-178.

Wakefield, J. (2015). DSM-5, psychiatric epidemiology and the false positives problem. Epidemiology of Psychiatric Science, 24(3), 188-196.

Wakefield, J., Demazeux, S. (2016) Sadness or Depression?: International perspectives on the depression epidemic and its meaning. Amsterdam: Springer.

Wang, S-M., Han, C., Lee, S-J., J. T-Y., Patkar, A. A., Masand, P. S., Pae, C-U. (2018). Efficacy of antidepressants: bias in randomized clinical trials and related issues. Expert Review in Clinical Pharmacology, 11(1), 15-25.

Williams, R. D. (2018). Melancholy and the infinite treatments: An investigative study into the marketing of antidepressants (Tesis Doctoral). Universidad de Cardiff.

Williams, S. J., Martin, P., Gabe, J. (2011). The pharmaceuticalisation of society? A framework for analysis. Sociology of Health & Illness, 33(5), 710-725.

Withaker, R. (2018). Anatomía de una epidemia. Madrid: Capitan Swing.

Withley, R. (2012). The antipsychiatric movement: Dead, diminishing or developing? Psychiatric Services, 63(10), 1039-1041.

Zetterqvist, A. V., Mulinari, S. (2013). Misleading advertising for antidepressants in Sweden failure of pharmaceutical industry self-regulation. POS ONE, 8(5), 1-12.
Monterde Fuertes, A. (2022). The Epidemic of Depression: When Science Doesn’t Correct Itself. ArtefaCToS. Revista De Estudios Sobre La Ciencia Y La tecnología, 11(2), 5–28.


Download data is not yet available.